Metabolic Syndrome in Schizophrenia
Open Access
- 1 July 2013
- journal article
- review article
- Published by SAGE Publications in Indian Journal of Psychological Medicine
- Vol. 35 (3), 227-240
- https://doi.org/10.4103/0253-7176.119471
Abstract
To review the data with respect to prevalence of metabolic syndrome (MetS) and its correlates in schizophrenia. For this review, electronic search engines PUBMED, Sciencedirect, and Google Scholar were used. Available data suggests that most of the studies have been of cross-sectional design. Prevalence rates of MetS have varied from 11% to 69% in medicated patients, and 4-26% in drug naive patients in cross-sectional evaluations. Longitudinal studies have shown the prevalence rates to range from 0% to 14% at the baseline in drug naive patients, which increase to as high as 52.4% by 3 months of antipsychotic medication treatment. The prevalence rates of MetS in patients with schizophrenia are much higher than that seen in general population or healthy controls. Though there is no causal association with any demographic or clinical variables, the risk increases with increase in age. Among antipsychotics, there seems to be an association between MetS and atypical antipsychotics like clozapine and olanzapine. Therefore, the psychiatrists should be more vigilant regarding the presence of MetS in these high risk groups. Research on biological correlates of MetS in schizophrenia is still in its primitive stage, however, these is some evidence to suggest an association of MetS with adiponectin levels, hematological indices, methylenetetrahydrofolate reductase (MTHFR) and Alpha-1A adrenergic receptor (ADRA1A) gene. These areas hold promise, and targeting these with appropriate interventions may help us to prevent the occurrence of MetS in patients with schizophrenia in future.Keywords
This publication has 105 references indexed in Scilit:
- Risk Factors Associated With Metabolic Syndrome in Bipolar and Schizophrenia Subjects Treated With AntipsychoticsJournal of Clinical Psychopharmacology, 2012
- Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional studyBMC Psychiatry, 2011
- Cardiovascular risk in a first-episode psychosis sample: A ‘critical period’ for prevention?Schizophrenia Research, 2011
- Harmonizing the Metabolic SyndromeCirculation, 2009
- The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one yearJournal of Psychiatric Research, 2009
- Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1Schizophrenia Research, 2008
- Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variantsSchizophrenia Research, 2007
- A Systematic Review of Mortality in SchizophreniaArchives of General Psychiatry, 2007
- Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up studyBMC Psychiatry, 2007
- Does antipsychotic polypharmacy increase the risk for metabolic syndrome?Schizophrenia Research, 2006